Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indoximod and Temozolomide in Refractory Brain Tumors
NCT02052648Phase 2Completed
- Sponsor
- Lumos Pharma, Inc.
- Start
- Mar 2014
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of indoximod in glioblastoma multiforme (GBM), Gliosarcoma (GS), glioma, sponsored by Lumos Pharma, Inc.. Started Mar 2014; status: completed.
02
Drugs
indoximod
03
Conditions
glioblastoma multiforme (GBM)Gliosarcoma (GS)glioma
Beyond the preview
Go deeper on NCT02052648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02052648.